Errik Anderson sits down with David Weisburd to discuss Pro-noia, the potential of the biotech industry, and the 82VS Seed Fund investment approach. They discuss practicing Pro-noia, the value of building a portfolio of relationships, and the idea of a forever company.
The 10X Capital Podcast is part of the Turpentine podcast network. Learn more: turpentine.co
--
X / Twitter:
@errikanderson (Errik)
@dweisburd (David)
--
LINKS:
82VS: https://alloytx.com/venture-studios/
Alloy Therapeutics: https://alloytx.com/
--
NEWSLETTER:
By popular demand, we’ve launched the 10X Capital Podcast newsletter, which offer’s this week’s venture capital and limited partner news in digestible news bites delivered straight to your email. To subscribe please visit: http://10xcapital.beehiiv.com/
The 10X Capital Podcast Newsletter is powered by Ikaria Labs, a full-service content marketing firm that partners with the top funds, fintechs, and financial services firms to grow their investor communities. To learn more, visit: https://www.ikarialabs.xyz/
--
Questions or topics you want us to discuss on The 10X Capital Podcast? Email us at david@10xcapital.com
--
TIMESTAMPS
(0:00) Episode Preview
(10:22) The potential scale of platform building in the biotech industry
(20:22) Leading with work and following with capital - the approach at 82VS Seed Fund
(28:13) Practicing Pro-noia: Cultivating optimism and generosity
(33:35) Building a portfolio of relationships and the compounding value
(40:01) Errik Anderson on involving his family in his work
(46:00) Errik Anderson's management style: micro-managing or detailed involvement?
(54:09) Errik Anderson explains the concept of a forever company
(57:00) Collaborating with big pharmaceutical companies like Pfizer
(1:00:56) 10X Capital Podcast Newsletter
